Physician profile
John M Depietro
NPI 1194856120
$18,095.44
in general payments reported to CMS, 2019-2025
24 companies · $2,909 in 2025
The $2,909 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,852 · 2022: $4,162 · 2023: $3,439 · 2024: $4,733 · 2025: $2,909.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,743 · Travel and Lodging: $2,339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,742.78 |
| Travel and Lodging | $2,338.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $13,453.75 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Aveir |
| Abiomed | $850.34 | 2022-2025 | Impella |
| Alnylam Pharmaceuticals INC. | $563.21 | 2021-2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $541.99 | 2021-2025 | Farxiga, Wainua, Lokelma |
| Novartis Pharmaceuticals Corporation | $447.91 | 2021-2023 | |
| Actelion Pharmaceuticals US, INC. | $388.39 | 2023-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $364.18 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $336.06 | 2022-2025 | Verquvo, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.59 | 2022-2025 | Jardiance |
| Solventum Corporation | $139.61 | 2025 | V.A.C.Ulta, V.A.C. Veraflo, Prevena |
| Edwards Lifesciences Corporation | $125.00 | 2025 | |
| Vifor Pharma, INC. | $102.20 | 2021-2023 | Veltassa |
| Pfizer INC. | $97.76 | 2022 | |
| Scpharmaceuticals INC. | $76.32 | 2023-2025 | |
| Impulse Dynamics (USA) INC. | $51.93 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $51.49 | 2021-2022 | |
| Novo Nordisk INC | $49.41 | 2025 | Rybelsus, Ozempic |
| Akcea Therapeutics, INC. | $40.33 | 2021 | |
| Boston Scientific Corporation | $28.21 | 2021-2022 | |
| Daxor Corporation | $25.27 | 2023 | Bva-100 |
| Medtronic, INC. | $23.10 | 2023 | Linq II |
| Lexicon Pharmaceuticals, INC. | $16.68 | 2023 | Inpefa |
| Chiesi USA, INC. | $15.41 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $14.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Depietro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.